Cerebrolysin (60mg)
Spécifications techniques
| Pureté (HPLC) | Pharmaceutical-grade standardized hydrolysate |
| Numéro CAS | 12656-61-0 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | Mixture of low-molecular-weight neuropeptides and free amino acids (<10 kDa fraction) |
| Forme saline | Acetate |
| Solubilité | Aqueous formulation, pH ~5.5-6.5 |
Cerebrolysin (60mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)40,50 EUR
- Hongrie (HU)40,50 EUR≈ 16 200 Ft
- Slovaquie (SK)40,50 EUR
- Tchéquie (CZ)40,50 EUR≈ 1 013 Kč
- Pologne (PL)40,50 EUR≈ 172,13 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Neurotrophic peptide complex for cognitive and neuroprotection research. 60mg vial.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
A parenteral neuropeptide preparation produced by controlled enzymatic breakdown of purified porcine brain proteins. Contains active low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors, with demonstrated neuroprotective and neurotrophic activity across stroke, TBI, and dementia models.
Key Mechanisms
- ›Neurotrophic factor-like activity (BDNF, GDNF, NGF mimetic)
- ›Reduction of excitotoxicity and free-radical damage
- ›Inhibition of calpain-mediated apoptosis
- ›Enhanced neurogenesis in dentate gyrus
- ›Modulation of microglial inflammation
Primary Research Areas
- ›Ischemic stroke recovery
- ›Traumatic brain injury
- ›Vascular dementia
- ›Alzheimer's disease research
- ›Neurodevelopmental models
Key Research Findings
- CASTA trial: significant functional improvement after acute ischemic stroke (Heiss et al., 2012)
- Dose-dependent cognitive improvement in mild-to-moderate Alzheimer's (Álvarez et al., Neurobiol Aging 2006)
- Reduced infarct volume and apoptosis in rodent MCAO models
Research Overview
A parenteral neuropeptide preparation produced by controlled enzymatic breakdown of purified porcine brain proteins. Contains active low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors, with demonstrated neuroprotective and neurotrophic activity across stroke, TBI, and dementia models.
Origin: Enzymatically standardized hydrolysate of purified porcine brain proteins; clinically used in Europe and Asia
Mechanism of Action
- Neurotrophic factor-like activity (BDNF, GDNF, NGF mimetic)
- Reduction of excitotoxicity and free-radical damage
- Inhibition of calpain-mediated apoptosis
- Enhanced neurogenesis in dentate gyrus
- Modulation of microglial inflammation
Primary Research Areas
- Ischemic stroke recovery
- Traumatic brain injury
- Vascular dementia
- Alzheimer's disease research
- Neurodevelopmental models
Key Published Findings
- CASTA trial: significant functional improvement after acute ischemic stroke (Heiss et al., 2012)
- Dose-dependent cognitive improvement in mild-to-moderate Alzheimer's (Álvarez et al., Neurobiol Aging 2006)
- Reduced infarct volume and apoptosis in rodent MCAO models
Research Protocol
Commonly studied routes: Intravenous, Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
Store below 25°C. Protect from light. Do not freeze
Important Notice
Cerebrolysin (60mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Aqueous formulation, pH ~5.5-6.5